Pharmacologic Management of High-Risk Neuroblastoma in Children

被引：0

作者：

Veena R. Ganeshan

Nina F. Schor

机构：

[1] University of Rochester School of Medicine and Dentistry,Center for Neural Development and Disease, and Department of Pediatrics

[2] University of Rochester Medical Center,Department of Pediatrics

来源：

Pediatric Drugs | 2011年 / 13卷

关键词：

Neuroblastoma; Topotecan; Minimal Residual Disease; Anaplastic Lymphoma Kinase; Isotretinoin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Neuroblastoma is the most common extracranial solid tumor of childhood. It accounts for 15% of pediatric cancer deaths. Children with high-risk disease have a 3-year event-free survival rate of only 20%. Chemotherapy is the mainstay of treatment in children with advanced neuroblastoma.

引用

页码：245 / 255

页数：10

共 50 条

[41] High-Risk Neuroblastoma Treatment Review
Smith, Valeria
Foster, Jennifer
CHILDREN-BASEL, 2018, 5 (09):
[42] The genetic landscape of high-risk neuroblastoma
Trevor J Pugh
Olena Morozova
Edward F Attiyeh
Shahab Asgharzadeh
Jun S Wei
Daniel Auclair
Scott L Carter
Kristian Cibulskis
Megan Hanna
Adam Kiezun
Jaegil Kim
Michael S Lawrence
Lee Lichenstein
Aaron McKenna
Chandra Sekhar Pedamallu
Alex H Ramos
Erica Shefler
Andrey Sivachenko
Carrie Sougnez
Chip Stewart
Adrian Ally
Inanc Birol
Readman Chiu
Richard D Corbett
Martin Hirst
Shaun D Jackman
Baljit Kamoh
Alireza Hadj Khodabakshi
Martin Krzywinski
Allan Lo
Richard A Moore
Karen L Mungall
Jenny Qian
Angela Tam
Nina Thiessen
Yongjun Zhao
Kristina A Cole
Maura Diamond
Sharon J Diskin
Yael P Mosse
Andrew C Wood
Lingyun Ji
Richard Sposto
Thomas Badgett
Wendy B London
Yvonne Moyer
Julie M Gastier-Foster
Malcolm A Smith
Jaime M Guidry Auvil
Daniela S Gerhard
Nature Genetics, 2013, 45 : 279 - 284
[43] Eflornithine for treatment of high-risk neuroblastoma
Jiang, Jianxiong
Yu, Ying
TRENDS IN PHARMACOLOGICAL SCIENCES, 2024, 45 (06) : 577 - 578
[44] Dinutuximab: A Review in High-Risk Neuroblastoma
Hoy, Sheridan M.
TARGETED ONCOLOGY, 2016, 11 (02) : 247 - 253
[45] A Safer Regimen for High-Risk Neuroblastoma
Felix, Carolyn A.
PEDIATRIC BLOOD & CANCER, 2009, 53 (01) : 3 - 6
[46] Immunocombination therapy for high-risk neuroblastoma
Kroesen, Michiel
Lindau, Dennis
Hoogerbrugge, Peter
Adema, Gosse J.
IMMUNOTHERAPY, 2012, 4 (02) : 163 - 174
[47] Rethinking high-risk neuroblastoma treatment
Cohn, Susan L.
Pearson, Andrew D. J.
PEDIATRIC BLOOD & CANCER, 2022, 69 (08)
[48] The genetic landscape of high-risk neuroblastoma
Pugh, Trevor J.
Morozova, Olena
Attiyeh, Edward F.
Asgharzadeh, Shahab
Wei, Jun S.
Auclair, Daniel
Carter, Scott L.
Cibulskis, Kristian
Hanna, Megan
Kiezun, Adam
Kim, Jaegil
Lawrence, Michael S.
Lichenstein, Lee
McKenna, Aaron
Pedamallu, Chandra Sekhar
Ramos, Alex H.
Shefler, Erica
Sivachenko, Andrey
Sougnez, Carrie
Stewart, Chip
Ally, Adrian
Birol, Inanc
Chiu, Readman
Corbett, Richard D.
Hirst, Martin
Jackman, Shaun D.
Kamoh, Baljit
Khodabakshi, Alireza Hadj
Krzywinski, Martin
Lo, Allan
Moore, Richard A.
Mungall, Karen L.
Qian, Jenny
Tam, Angela
Thiessen, Nina
Zhao, Yongjun
Cole, Kristina A.
Diamond, Maura
Diskin, Sharon J.
Mosse, Yael P.
Wood, Andrew C.
Ji, Lingyun
Sposto, Richard
Badgett, Thomas
London, Wendy B.
Moyer, Yvonne
Gastier-Foster, Julie M.
Smith, Malcolm A.
Auvil, Jaime M. Guidry
Gerhard, Daniela S.
NATURE GENETICS, 2013, 45 (03) : 279 - 284
[49] The Role of Surgery in High-risk Neuroblastoma
Ryan, Anne L.
Akinkuotu, Adesola
Pierro, Agostino
Morgenstern, Daniel A.
Irwin, Meredith S.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2020, 42 (01) : 1 - 7
[50] Evolving treatments in high-risk neuroblastoma
Kumar, Abhinav
Rocke, John P. J.
Kumar, B. Nirmal
EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (12): : 497 - 506

← 1 2 3 4 5 →